Moses Rodriguez

List of Publications by Year
in descending order

334 papers	23,412 citations	14655 66 h-index	10158 140 g-index
342 all docs	342 docs citations	342 times ranked	15841 citing authors

#	Article	IF	Citations
1	Multiple Sclerosis. New England Journal of Medicine, 2000, 343, 938-952.	27.0	3,121
2	Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Annals of Neurology, 2000, 47, 707-717.	5.3	2,892
3	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Annals of Neurology, 1999, 46, 878-886.	5.3	832
4	Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis. Brain Pathology, 1996, 6, 259-274.	4.1	712
5	Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Scientific Reports, 2016, 6, 28484.	3.3	660
6	Humoral autoimmunity as a mediator of CNS repair. Trends in Neurosciences, 2001, 24, 39-44.	8.6	525
7	A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. Brain, 1999, 122, 2279-2295.	7.6	436
8	Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet, The, 2005, 366, 579-582.	13.7	411
9	Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis. Annals of Neurology, 1983, 13, 426-433.	5.3	258
10	The relevance of animal models in multiple sclerosis research. Pathophysiology, 2011, 18, 21-29.	2.2	244
11	Immunoglobulins promote remyelination in the central nervous system. Annals of Neurology, 1990, 27, 12-17.	5.3	223
12	Human Gut-Derived Commensal Bacteria Suppress CNS Inflammatory and Demyelinating Disease. Cell Reports, 2017, 20, 1269-1277.	6.4	218
13	Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nature Medicine, 1998, 4, 187-193.	30.7	208
14	Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 188-198.	3.0	205
15	Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Annals of Neurology, 2004, 56, 303-306.	5.3	197
16	Remyelination in multiple sclerosis. Multiple Sclerosis Journal, 1997, 3, 133-136.	3.0	180
17	Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination. Archives of Neurology, 2011, 68, 870.	4.5	173
18	Efficient central nervous system remyelination requires T cells. Annals of Neurology, 2003, 53, 680-684.	5.3	169

#	Article	IF	Citations
19	Primary demyelination in transgenic mice expressing interferon-Î³. Nature Medicine, 1997, 3, 1037-1041.	30.7	167
20	Myasthenia gravis in children: Long-term follow-up. Annals of Neurology, 1983, 13, 504-510.	5.3	164
21	Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Annals of Neurology, 1992, 31, 262-267.	5.3	151
22	Ultrastructure of Multiple Sclerosis. Ultrastructural Pathology, 1994, 18, 3-13.	0.9	144
23	Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology, 2017, 88, 1623-1629.	1.1	138
24	Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factorâ€Î± in the central nervous system. European Journal of Immunology, 1997, 27, 905-913.	2.9	137
25	Gut microbiota composition and relapse risk in pediatric MS: A pilot study. Journal of the Neurological Sciences, 2016, 363, 153-157.	0.6	137
26	Viral perturbation of endocrine function: disordered cell function leads to disturbed homeostasis and disease. Nature, 1984, 307, 278-281.	27.8	132
27	Acceleration in the Rate of CNS Remyelination in Lysolecithin-Induced Demyelination. Journal of Neuroscience, 1998, 18, 2498-2505.	3.6	127
28	Oligodendrocyte Injury Is an Early Event in Lesions of Multiple Sclerosis. Mayo Clinic Proceedings, 1993, 68, 627-636.	3.0	124
29	A recombinant human IgM promotes myelin repair after a single, very low dose. Journal of Neuroscience Research, 2007, 85, 967-976.	2.9	124
30	Cognitive Impairment Occurs in Children and Adolescents With Multiple Sclerosis. Journal of Child Neurology, 2013, 28, 102-107.	1.4	121
31	Retinocochleocerebral Vasculopathy. Medicine (United States), 1998, 77, 12-40.	1.0	118
32	Quality of Life Is Favorable for Most Patients With Multiple Sclerosis. Archives of Neurology, 2004, 61, 679.	4.5	116
33	Prevalent Class I-Restricted T-Cell Response to the Theilerâ€™s Virus Epitope D^b:VP2_{121â€“130}in the Absence of Endogenous CD4 Help, Tumor Necrosis Factor Alpha, Gamma Interferon, Perforin, or Costimulation through CD28. Journal of Virology, 1999, 73, 3702-3708.	3.4	109
34	Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology, 1993, 43, 1100-1100.	1.1	109
35	Surface plasmon resonance for highâ€throughput ligand screening of membraneâ€bound proteins. Biotechnology Journal, 2009, 4, 1542-1558.	3.5	108
36	Perforin-Dependent Neurologic Injury in a Viral Model of Multiple Sclerosis. Journal of Neuroscience, 1998, 18, 7306-7314.	3.6	107

#	Article	IF	Citations
37	Remyelination by Oligodendrocytes Stimulated by Antiserum to Spinal Cord. Journal of Neuropathology and Experimental Neurology, 1987, 46, 84-95.	1.7	104
38	Multiple Sclerosis. Neurologic Clinics, 2018, 36, 1-11.	1.8	103
39	Multiple Sclerosis Therapies in Pediatric Patients With Refractory Multiple Sclerosis. Archives of Neurology, 2011, 68, 437.	4.5	101
40	Quantitation of spinal cord demyelination, remyelination, atrophy, and axonal loss in a model of progressive neurologic injury. Journal of Neuroscience Research, 1999, 58, 492-504.	2.9	100
41	A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2â€weighted spinal cord MRI in a virusâ€induced murine model of MS. FASEB Journal, 2004, 18, 1577-1579.	0.5	100
42	Clinical features of neuromyelitis optica in children. Neurology, 2016, 86, 245-252.	1.1	100
43	Targeting of IgMÎº Antibodies to Oligodendrocytes Promotes CNS Remyelination. Journal of Neuroscience, 1998, 18, 7700-7708.	3.6	99
44	Concurrence of Inflammatory Bowel Disease and Multiple Sclerosis. Mayo Clinic Proceedings, 2000, 75, 802-806.	3.0	99
45	Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Annals of Neurology, 1992, 32, 834-835.	5.3	98
46	Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia, 2002, 37, 241-249.	4.9	98
47	Cross-linking the B7 Family Molecule B7-DC Directly Activates Immune Functions of Dendritic Cells. Journal of Experimental Medicine, 2002, 196, 1393-1398.	8.5	96
48	Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Movement Disorders, 2004, 19, 1482-1485.	3.9	96
49	Interferon-Î³ in Progression to Chronic Demyelination and Neurological Deficit Following Acute EAE. Molecular and Cellular Neurosciences, 1998, 12, 376-389.	2.2	94
50	Seizures in Patients with Multiple Sclerosis. CNS Drugs, 2009, 23, 805-815.	5.9	93
51	Relapses and disability accumulation in progressive multiple sclerosis. Neurology, 2015, 84, 81-88.	1.1	92
52	Targeting kallikrein 6â€proteolysis attenuates CNS inflammatory disease. FASEB Journal, 2004, 18, 920-922.	0.5	91
53	Characteristics of Children and Adolescents With Multiple Sclerosis. Pediatrics, 2016, 138, .	2.1	89
54	Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology, 2015, 85, 722-729.	1.1	86

#	Article	IF	Citations
55	Immunosuppression promotes CNS remyelination in chronic virusâ€induced demyelinating disease. Neurology, 1992, 42, 348-348.	1.1	84
56	The Potential for Oligodendrocyte Proliferation During Demyelinating Disease. Journal of Neuropathology and Experimental Neurology, 1993, 52, 55-63.	1.7	83
57	Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronicâ€progressive demyelinating disease. FASEB Journal, 2002, 16, 1325-1327.	0.5	81
58	Gamma Interferon Is Critical for Neuronal Viral Clearance and Protection in a Susceptible Mouse Strain following Early Intracranial Theiler's Murine Encephalomyelitis Virus Infection. Journal of Virology, 2003, 77, 12252-12265.	3.4	80
59	Enzymatic Properties of Rat Myelencephalon-Specific Protease. Biochemistry, 2002, 41, 1165-1173.	2.5	79
60	Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Molecular and Cellular Neurosciences, 2003, 22, 14-24.	2.2	79
61	In vivo magnetic resonance imaging of immune cells in the central nervous system with superparamagnetic antibodies. FASEB Journal, 2004, 18, 179-182.	0.5	78
62	MRI in Rodent Models of Brain Disorders. Neurotherapeutics, 2011, 8, 3-18.	4.4	76
63	CD8⁺T cells in multiple sclerosis. Expert Opinion on Therapeutic Targets, 2013, 17, 1053-1066.	3.4	76
64	Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis. Journal of Biological Chemistry, 2015, 290, 30697-30712.	3.4	76
65	Effectors of Demyelination and Remyelination in the CNS: Implications for Multiple Sclerosis. Brain Pathology, 2007, 17, 219-229.	4.1	75
66	Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 28-33.	1.9	74
67	Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB Journal, 2002, 16, 1260-1262.	0.5	71
68	Virus-Induced Demyelination in Mice: â€œDying Backâ€•of Oligodendrocytes. Mayo Clinic Proceedings, 1985, 60, 433-438.	3.0	70
69	The treatable dementia of sjÃ¶gren's syndrome. Annals of Neurology, 1991, 30, 98-101.	5.3	68
70	Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biological Chemistry, 2008, 389, 739-745.	2.5	68
71	Realâ€World Effectiveness of Initial Diseaseâ€Modifying Therapies in Pediatric <scp>Multiple Sclerosis</scp>. Annals of Neurology, 2020, 88, 42-55.	5.3	68
72	Interleukin-6 Protects Anterior Horn Neurons from Lethal Virus-Induced Injury. Journal of Neuroscience, 2003, 23, 481-492.	3.6	67

#	Article	IF	Citations
73	Distinct effects of obesity and puberty on risk and age at onset of pediatric MS. Annals of Clinical and Translational Neurology, 2016, 3, 897-907.	3.7	67
74	Quantitative Assessment of Neurologic Deficits in a Chronic Progressive Murine Model of CNS Demyelination. Experimental Neurology, 1999, 158, 171-181.	4.1	66
75	MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. Journal of Comparative Neurology, 2001, 431, 347-361.	1.6	65
76	Preservation of motor function by inhibition of CD8+ virus peptideâ€specific T cells in Theiler's virus infection. FASEB Journal, 2001, 15, 1-22.	0.5	65
77	Naturally Occurring Human IgM Antibody That Binds B7-DC and Potentiates T Cell Stimulation by Dendritic Cells. Journal of Immunology, 2003, 170, 1830-1838.	0.8	65
78	Is Multiple Sclerosis an Autoimmune Disease?. Autoimmune Diseases, 2012, 2012, 1-12.	0.6	63
79	Magnetic resonance imaging, microscopy, and spectroscopy of the central nervous system in experimental animals. NeuroRx, 2005, 2, 250-264.	6.0	62
80	Clearance of Theiler's virus infection depends on the ability to generate a CD8⁺ Tâ€„cell response against a single immunodominant viral peptide. European Journal of Immunology, 2003, 33, 2501-2510.	2.9	61
81	Immunotherapeutic Potential of B7-DC (PD-L2) Cross-Linking Antibody In Conferring Antitumor Immunity. Cancer Research, 2004, 64, 4965-4972.	0.9	61
82	Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiology of Disease, 2004, 15, 120-131.	4.4	60
83	Quantitative Ultrastructural Analysis of a Single Spinal Cord Demyelinated Lesion Predicts Total Lesion Load, Axonal Loss, and Neurological Dysfunction in a Murine Model of Multiple Sclerosis. American Journal of Pathology, 2000, 157, 1365-1376.	3.8	59
84	A function of myelin is to protect axons from subsequent injury: implications for deficits in multiple sclerosis. Brain, 2003, 126, 751-752.	7.6	58
85	Dietary salt intake and time to relapse in paediatric multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1350-1353.	1.9	58
86	A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 6, 87-92.	2.0	58
87	Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune Cells. International Journal of Molecular Sciences, 2019, 20, 5500.	4.1	58
88	Antiviral immune responses modulate the nature of central nervous system (CNS) disease in a murine model of multiple sclerosis. Immunological Reviews, 1997, 159, 177-193.	6.0	57
89	Absence of perforin expression confers axonal protection despite demyelination. Neurobiology of Disease, 2007, 25, 354-359.	4.4	56
90	Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology, 2018, 91, e1778-e1787.	1.1	55

#	Article	IF	Citations
91	Inhibition of Theiler's Virus-induced demylination in vivo by tumor necrosis factor alpha. International Immunology, 1990, 2, 909-913.	4.0	54
92	Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis. Archives of Neurology, 2006, 63, 611.	4.5	54
93	Microangiopathy of vasa nervorum in dysglobulinemic neuropathy. Annals of Neurology, 1984, 15, 386-394.	5.3	53
94	Pediatric Multiple Sclerosis. Neurologic Clinics, 2011, 29, 481-505.	1.8	53
95	Multiple Sclerosis: Basic Concepts and Hypothesis. Mayo Clinic Proceedings, 1989, 64, 570-576.	3.0	52
96	Later-Onset Fabry Disease. Archives of Neurology, 2006, 63, 453.	4.5	52
97	Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia, 2010, 58, 1782-1793.	4.9	52
98	Effect of cyclosporin A, silica quartz dust, and protease inhibitors on virus-induced demyelination. Journal of Neuroimmunology, 1986, 13, 159-174.	2.3	51
99	PDGF is Required for Remyelination-Promoting IgM Stimulation of Oligodendrocyte Progenitor Cell Proliferation. PLoS ONE, 2013, 8, e55149.	2.5	51
100	Immune-mediated injury of virus-infected oligodendrocytes A model of multiple sclerosis. Trends in Immunology, 1986, 7, 359-363.	7.5	50
101	Disrupted spatial memory is a consequence of picornavirus infection. Neurobiology of Disease, 2006, 24, 266-273.	4.4	50
102	Humoral autoimmunity as a mediator of CNS repair. Trends in Neurosciences, 2001, 24, S39-S44.	8.6	49
103	Facile Assembly of Micro- and Nanoarrays for Sensing with Natural Cell Membranes. ACS Nano, 2011, 5, 7555-7564.	14.6	49
104	H-2 Ddtransgene suppresses Theiler's virus-induced demyelination in susceptible strains of mice. Journal of NeuroVirology, 1995, 1, 111-117.	2.1	48
105	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genetics, 2019, 15, e1007808.	3.5	48
106	Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosis. Acta Neuropathologica, 2020, 140, 143-167.	7.7	48
107	Complementation between specific HLA-DR and HLA-DQ genes in transgenic mice determines susceptibility to experimental autoimmune encephalomyelitis. Human Immunology, 2000, 61, 279-289.	2.4	47
108	Cellular Mechanisms of Central Nervous System Repair by Natural Autoreactive Monoclonal Antibodies. Archives of Neurology, 2009, 66, 1456-9.	4.5	47

#	Article	IF	Citations
109	VP1 and VP2 Capsid Proteins of Theiler's Virus Are Targets of H-2D-Restricted Cytotoxic Lymphocytes in the Central Nervous System of B10 Mice. Virology, 1995, 214, 91-99.	2.4	46
110	Seizures in Patients With Multiple Sclerosis Seen at Mayo Clinic, Rochester, Minn, 1990â€“1998. Mayo Clinic Proceedings, 2001, 76, 983-986.	3.0	46
111	Neuron-Binding Human Monoclonal Antibodies Support Central Nervous System Neurite Extension. Journal of Neuropathology and Experimental Neurology, 2004, 63, 461-473.	1.7	46
112	Enhancing CNS Repair in Neurological Disease. CNS Drugs, 2011, 25, 555-573.	5.9	45
113	Two discreet subsets of CD8 T cells modulate PLP91â€“110 induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice. Journal of Autoimmunity, 2012, 38, 344-353.	6.5	45
114	Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain, 2020, 143, 2733-2741.	7.6	45
115	Clonal evolution in Waldenstrom macroglobulinemia highlights functional role of B-cell receptor. Blood, 2001, 97, 321-323.	1.4	43
116	Invited Article: Human natural autoantibodies in the treatment of neurologic disease. Neurology, 2009, 72, 1269-1276.	1.1	43
117	Demyelinated Axons and Motor Function Are Protected by Genetic Deletion of Perforin in a Mouse Model of Multiple Sclerosis. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1037-1048.	1.7	43
118	Successful treatment of established relapsing experimental autoimmune encephalomyelitis in mice with a monoclonal natural autoantibody. Journal of Neuroimmunology, 1997, 75, 204-209.	2.3	42
119	Ebola virus: Melatonin as a readily available treatment option. Journal of Medical Virology, 2015, 87, 537-543.	5.0	42
120	Theiler's virus-induced demyelination in mice immunosuppressed with anti-IgM and in mice expressing the xid gene. Microbial Pathogenesis, 1990, 8, 23-35.	2.9	41
121	Proteolipid Protein Gene Expression in Demyelination and Remyelination of the Central Nervous System: A Model for Multiple Sclerosis. Journal of Neuropathology and Experimental Neurology, 1994, 53, 136-143.	1.7	41
122	CD8+ T cells directed against a viral peptide contribute to loss of motor function by disrupting axonal transport in a viral model of fulminant demyelination. Journal of Neuroimmunology, 2007, 188, 13-21.	2.3	41
123	Remyelination Induced by a DNA Aptamer in a Mouse Model of Multiple Sclerosis. PLoS ONE, 2012, 7, e39595.	2.5	41
124	Central neurogenic hyperventilation in an awake patient with brainstem astrocytoma. Annals of Neurology, 1982, 11, 625-628.	5.3	40
125	Growth factor treatment of demyelinating disease: at last, a leap into the light. Trends in Immunology, 2002, 23, 512-516.	6.8	40
126	Effects of Transforming Growth Factorâ€Î² and Plateletâ€Derived Growth Factor on Oligodendrocyte Precursors: Insights Gained from a Neuronal Cell Line. Journal of Neurochemistry, 1997, 68, 2281-2290.	3.9	40

#	Article	IF	Citations
127	A monoclonal autoantibody which promotes central nervous system remyelination is highly polyreactive to multiple known and novel antigens. Journal of Neuroimmunology, 1996, 65, 11-19.	2.3	39
128	The Controversy Surrounding the Pathogenesis of the Multiple Sclerosis Lesion. Mayo Clinic Proceedings, 1997, 72, 665-678.	3.0	39
129	Identification of T cell epitopes on human proteolipid protein and induction of experimental autoimmune encephalomyelitis in HLA classâ€„II-transgenic mice. European Journal of Immunology, 2004, 34, 280-290.	2.9	39
130	Direct Comparison of Demyelinating Disease Induced by the Daniel's Strain and BeAn Strain of Theiler's Murine Encephalomyelitis Virus. Brain Pathology, 2003, 13, 291-308.	4.1	39
131	Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: The Mayo Clinic experience. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1178-1186.	0.8	39
132	Erichrome Stain for Myelin on Osmicated Tissue Embedded in Glycol Methacrylate Plastic. Journal of Histotechnology, 1989, 12, 35-36.	0.5	38
133	Central nervous system demyelination and remyelination in multiple sclerosis and viral models of disease. Journal of Neuroimmunology, 1992, 40, 255-263.	2.3	38
134	Differential generation of class I H-2D- versus H-2K-restricted cytotoxicity against a demyelinating virus following central nervous system infection. European Journal of Immunology, 1997, 27, 963-970.	2.9	38
135	High-Affinity Binding of Remyelinating Natural Autoantibodies to Myelin-Mimicking Lipid Bilayers Revealed by Nanohole Surface Plasmon Resonance. Analytical Chemistry, 2012, 84, 6031-6039.	6.5	38
136	A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis. DMM Disease Models and Mechanisms, 2015, 8, 831-42.	2.4	38
137	TGF-Î²2 Reduces Demyelination, Virus Antigen Expression, and Macrophage Recruitment in a Viral Model of Multiple Sclerosis. Journal of Immunology, 2000, 164, 3207-3213.	0.8	37
138	Antibody-mediated remyelination operates through mechanism independent of immunomodulation. Journal of Neuroimmunology, 2004, 146, 153-161.	2.3	37
139	Genetic risk factors for pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1825-1834.	3.0	37
140	More severe neurologic deficits in SJL/J male than female mice following Theilerâ€™s virus-induced CNS demyelination. Experimental Neurology, 2003, 180, 14-24.	4.1	36
141	Dynamics of MRI lesion development in an animal model of viral-induced acute progressive CNS demyelination. NeuroImage, 2004, 21, 576-582.	4.2	36
142	Antigen-Specific CD8+ T Cells Mediate a Peptide-Induced Fatal Syndrome. Journal of Immunology, 2005, 174, 6854-6862.	0.8	36
143	Differential Influence of Interleukin-12 in the Pathogenesis of Autoimmune and Virus-Induced Central Nervous System Demyelination. Journal of Virology, 1999, 73, 1637-1639.	3.4	36
144	HLA-DQ8 (DQB1*0302)-Restricted Th17 Cells Exacerbate Experimental Autoimmune Encephalomyelitis in HLA-DR3-Transgenic Mice. Journal of Immunology, 2009, 182, 5131-5139.	0.8	35

#	Article	IF	Citations
145	Central Nervous System Remyelination Clinical Application of Basic Neuroscience Principles. Brain Pathology, 1996, 6, 331-344.	4.1	34
146	Preferential expression of myelencephalon-specific protease by oligodendrocytes of the adult rat spinal cord white matter. , 2000, 30, 219-230.		34
147	HLA DR and DQ interaction in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in HLA class II transgenic mice. Journal of Neuroimmunology, 2005, 169, 1-12.	2.3	34
148	CD8+ T Cells Cause Disability and Axon Loss in a Mouse Model of Multiple Sclerosis. PLoS ONE, 2010, 5, e12478.	2.5	34
149	Autoantibodies with enzymatic properties in human autoimmune diseases. Journal of Autoimmunity, 2011, 37, 144-150.	6.5	34
150	Kallikrein 6 Regulates Early CNS Demyelination in a Viral Model of Multiple Sclerosis. Brain Pathology, 2012, 22, 709-722.	4.1	34
151	Absence of IFN-Î³ Increases Brain Pathology in Experimental Autoimmune Encephalomyelitisâ€“Susceptible DRB1*0301.DQ8 HLA Transgenic Mice through Secretion of Proinflammatory Cytokine IL-17 and Induction of Pathogenic Monocytes/Microglia into the Central Nervous System. Journal of Immunology, 2014, 193, 4859-4870.	0.8	34
152	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	3.0	34
153	Role of T cells in resistance to Theiler's virus infection. Microbial Pathogenesis, 1991, 11, 269-281.	2.9	33
154	Acute hemorrhagic demyelination in a murine model of multiple sclerosis. Journal of Neuroinflammation, 2008, 5, 31.	7.2	33
155	Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination. Expert Review of Neurotherapeutics, 2010, 10, 441-457.	2.8	33
156	Multiple sclerosis: The role of melatonin and N-acetylserotonin. Multiple Sclerosis and Related Disorders, 2015, 4, 112-123.	2.0	33
157	Age is a critical determinant in recovery from multiple sclerosis relapses. Multiple Sclerosis Journal, 2019, 25, 1754-1763.	3.0	33
158	A monoclonal natural autoantibody that promotes remyelination suppresses central nervous system inflammation and increases virus expression after Theiler's virus-induced demyelination. International Immunology, 1996, 8, 131-141.	4.0	32
159	The Controversy Surrounding the Pathogenesis of the Multiple Sclerosis Lesion. Mayo Clinic Proceedings, 1997, 72, 665-678.	3.0	32
160	Monoclonal remyelination-promoting natural autoantibody SCH 94.03: pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosis. Journal of the Neurological Sciences, 1997, 150, 103-113.	0.6	32
161	Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 891-895.	3.0	32
162	Subacute encephalomyelitis presenting as stiff-person syndrome: Clinical, polygraphic, and pathologic correlations. Movement Disorders, 1996, 11, 701-709.	3.9	30

#	Article	IF	Citations
163	Absence of Spontaneous Central Nervous System Remyelination in Class II-deficient Mice Infected with TheilerÊ¼s Virus. Journal of Neuropathology and Experimental Neurology, 1999, 58, 78-91.	1.7	30
164	Cellular sources and targets of IFN-Î³-mediated protection against viral demyelination and neurological deficits. European Journal of Immunology, 2002, 32, 606.	2.9	30
165	Sublethal oligodendrocyte injury: A reversible condition in multiple sclerosis?. Annals of Neurology, 2017, 81, 811-824.	5.3	30
166	Polyclonal and Monoclonal Antibodies in Clinic. Methods in Molecular Biology, 2014, 1060, 79-110.	0.9	30
167	Internalization and Sorting of Plasma Membrane Sphingolipid Analogues in Differentiating Oligodendrocytes. Journal of Neurochemistry, 2002, 73, 1375-1383.	3.9	29
168	Urban air quality and associations with pediatric multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1146-1153.	3.7	29
169	Short-term treatment with interferon-?/? promotes remyelination, whereas long-term treatment aggravates demyelination in a murine model of multiple sclerosis. , 2000, 59, 661-670.		28
170	Immunoglobulin-mediated CNS repairâ˜†â˜†â˜†.... Journal of Allergy and Clinical Immunology, 2001, 108, S121-S125.	2.5	28
171	Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Multiple Sclerosis Journal, 2004, 10, 85-86.	3.0	28
172	Human Monoclonal IgM Antibody Promotes CNS Myelin Repair Independent of Fc Function. Brain Pathology, 2003, 13, 608-616.	4.1	28
173	Genetically Dominant Spinal Cord Repair in a Murine Model of Chronic Progressive Multiple Sclerosis. Journal of Neuropathology and Experimental Neurology, 2005, 64, 46-57.	1.7	27
174	Premenstrual Multiple Sclerosis Pseudoexacerbations. Archives of Neurology, 2006, 63, 1005.	4.5	27
175	Dietary factors and pediatric multiple sclerosis: A case-control study. Multiple Sclerosis Journal, 2018, 24, 1067-1076.	3.0	27
176	Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin. Current Pharmaceutical Design, 2016, 22, 6134-6141.	1.9	27
177	Acute Disseminated Encephalomyelitis After Accidental Injection of a Hog Vaccine: Successful Treatment With Plasmapheresis. Mayo Clinic Proceedings, 1998, 73, 1193-1195.	3.0	26
178	HLA class II transgenic mice authenticate restriction of myelin oligodendrocyte glycoprotein-specific immune response implicated in multiple sclerosis pathogenesis. International Immunology, 2003, 15, 535-546.	4.0	26
179	A human IgM signals axon outgrowth: coupling lipid raft to microtubules. Journal of Neurochemistry, 2011, 119, 100-112.	3.9	26
180	Spontaneous and induced remyelination in multiple sclerosis and the theiler's virus model of central nervous system demyelination. Microscopy Research and Technique, 1995, 32, 230-245.	2.2	25

#	Article	IF	Citations
181	CNS Cell Populations are Protected from Virusâ€Induced Pathology by Distinct Arms of the Immune System. Brain Pathology, 1999, 9, 21-31.	4.1	25
182	Theiler's Murine Encephalomyelitis Virus as a Vaccine Candidate for Immunotherapy. PLoS ONE, 2011, 6, e20217.	2.5	25
183	Evidence for the Role of B Cells and Immunoglobulins in the Pathogenesis of Multiple Sclerosis. Neurology Research International, 2011, 2011, 1-14.	1.3	25
184	AMP-Activated Protein Kinase Suppresses Autoimmune Central Nervous System Disease by Regulating M1-Type Macrophageâ€“Th17 Axis. Journal of Immunology, 2016, 197, 747-760.	0.8	25
185	Heterogeneity in association of remote herpesvirus infections and pediatric <scp>MS</scp>. Annals of Clinical and Translational Neurology, 2018, 5, 1222-1228.	3.7	25
186	Anatomical and Cellular Requirements for the Activation and Migration of Virus-Specific CD8+ T Cells to the Brain during Theiler's Virus Infection. Journal of Virology, 2005, 79, 3063-3070.	3.4	24
187	Activated microglia stimulate transcriptional changes in primary oligodendrocytes via IL-1Î². Neurobiology of Disease, 2006, 23, 731-739.	4.4	24
188	HLA-DQ6 (DQB1*0601)-Restricted T Cells Protect against Experimental Autoimmune Encephalomyelitis in HLA-DR3.DQ6 Double-Transgenic Mice by Generating Anti-Inflammatory IFN-Î³. Journal of Immunology, 2008, 180, 7747-7756.	0.8	24
189	Tumor Necrosis Factor Î± is Reparative via TNFR1 in the Hippocampus and via TNFR2 in the Striatum after Virusâ€Induced Encephalitis. Brain Pathology, 2009, 19, 12-26.	4.1	24
190	Treatment of multiple sclerosis in children and adolescents. Expert Opinion on Pharmacotherapy, 2010, 11, 505-520.	1.8	24
191	Novel Immunomodulatory Approaches for the Management of Multiple Sclerosis. Clinical Pharmacology and Therapeutics, 2013, 95, 32-44.	4.7	24
192	The Spectrum of Inflammatory Acquired Demyelinating Syndromes in Children. Seminars in Pediatric Neurology, 2017, 24, 189-200.	2.0	24
193	Coexpression of Class I Major Histocompatibility Antigen and Viral RNA in Central Nervous System of Mice Infected With Theiler's Virus: A Model for Multiple Sclerosis. Mayo Clinic Proceedings, 1992, 67, 829-838.	3.0	23
194	Oligodendrocyte-reactive O1, O4, and HNK-1 monoclonal antibodies are encoded by germline immunoglobulin genes. Molecular Brain Research, 1995, 34, 283-293.	2.3	23
195	Incidence of Seizures in Patients With Multiple Sclerosis: A Population-Based Study. Mayo Clinic Proceedings, 2002, 77, 910-912.	3.0	23
196	Protective environmental factors for neuromyelitis optica. Neurology, 2014, 83, 1923-1929.	1.1	23
197	Antiviral Protection via RdRP-Mediated Stable Activation of Innate Immunity. PLoS Pathogens, 2015, 11, e1005311.	4.7	23
198	The progeroid gene BubR1 regulates axon myelination and motor function. Aging, 2016, 8, 2667-2688.	3.1	23

#	Article	IF	Citations
199	Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases. Expert Review of Neurotherapeutics, 2014, 14, 449-463.	2.8	22
200	Quantitative PCR Analysis of DNA Aptamer Pharmacokinetics in Mice. Nucleic Acid Therapeutics, 2015, 25, 11-19.	3.6	22
201	Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease. Molecular Neurobiology, 2016, 53, 5217-5228.	4.0	22
202	Extensive Injury of Descending Neurons Demonstrated by Retrograde Labeling in a Virus-Induced Murine Model of Chronic Inflammatory Demyelination. Journal of Neuropathology and Experimental Neurology, 2000, 59, 664-678.	1.7	21
203	Transgenic Expression of Theiler's Murine Encephalomyelitis Virus Genes in H-2b Mice Inhibits Resistance to Virus-Induced Demyelination. Journal of Virology, 2002, 76, 7799-7811.	3.4	21
204	The US Network of Pediatric Multiple Sclerosis Centers. Journal of Child Neurology, 2015, 30, 1381-1387.	1.4	21
205	Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opinion on Biological Therapy, 2016, 16, 827-839.	3.1	21
206	Examining the contributions of environmental quality to pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 18, 164-169.	2.0	21
207	Gut microbiome is associated with multiple sclerosis activity in children. Annals of Clinical and Translational Neurology, 2021, 8, 1867-1883.	3.7	21
208	Membrane lymphotoxin is required for resistance to Theiler's virus infection. International Immunology, 2003, 15, 955-962.	4.0	20
209	Neutralization of chemokines RANTES and MIG increases virus antigen expression and spinal cord pathology during Theiler's virus infection. International Immunology, 2005, 17, 569-579.	4.0	20
210	Role of MHC class II expressing CD4+ T cells in proteolipid protein91â€“110-induced EAE in HLA-DR3 transgenic mice. European Journal of Immunology, 2006, 36, 3356-3370.	2.9	20
211	Brainstem ¹H nuclear magnetic resonance (NMR) spectroscopy: Marker of demyelination and repair in spinal cord. Annals of Neurology, 2009, 66, 559-564.	5.3	20
212	A Single Dose of Neuron-Binding Human Monoclonal Antibody Improves Spontaneous Activity in a Murine Model of Demyelination. PLoS ONE, 2011, 6, e26001.	2.5	20
213	Preclinical ¹H-MRS neurochemical profiling in neurological and psychiatric disorders. Bioanalysis, 2012, 4, 1787-1804.	1.5	20
214	Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response. Biological Chemistry, 2014, 395, 1063-1073.	2.5	20
215	Multiple sclerosis: a unique immunopathological syndrome of the central nervous system. Seminars in Immunopathology, 1995, 17, 89-105.	4.0	19
216	Assessment of hindlimb gait as a powerful indicator of axonal loss in a murine model of progressive CNS demyelination. Brain Research, 2000, 877, 396-400.	2.2	19

#	Article	IF	Citations
217	Incidence of Seizures in Patients With Multiple Sclerosis: A Population-Based Study. Mayo Clinic Proceedings, 2002, 77, 910-912.	3.0	19
218	Disappearing "T1 black holes" in an animal model of multiple sclerosis. Frontiers in Bioscience - Landmark, 2004, 9, 1222.	3.0	19
219	Method of Identifying Natural Antibodies for Remyelination. Journal of Clinical Immunology, 2010, 30, 50-55.	3.8	19
220	IgM Natural Autoantibodies in Physiology and the Treatment of Disease. Methods in Molecular Biology, 2019, 1904, 53-81.	0.9	19
221	Allelic variation in the Tyk2 and EGF genes as potential genetic determinants of CNS repair. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 792-797.	7.1	18
222	Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. Multiple Sclerosis Journal, 2020, 26, 1938-1947.	3.0	18
223	Molecular Characterization of a Nondemyelinating Variant of Danielâ€™s Strain of Theilerâ€™s Virus Isolated from a Persistently Infected Glioma Cell Line. Journal of Virology, 1998, 72, 1262-1269.	3.4	18
224	Abbreviated Exposure to Hypoxia Is Sufficient to Induce CNS Dysmyelination, Modulate Spinal Motor Neuron Composition, and Impair Motor Development in Neonatal Mice. PLoS ONE, 2015, 10, e0128007.	2.5	18
225	Theiler's virus-associated antigens on the surfaces of cultured glial cells. Virology, 1988, 166, 463-474.	2.4	17
226	Motor and somatosensory evoked potentials in mice infected with Theiler's murine encephalomyelitis virus. Journal of the Neurological Sciences, 1994, 123, 186-194.	0.6	17
227	Chapter 28 Immune promotion of central nervous system remyelination. Progress in Brain Research, 1994, 103, 343-355.	1.4	17
228	Antiviral Effects of a Transgenic RNA-Dependent RNA Polymerase. Journal of Virology, 2011, 85, 621-625.	3.4	17
229	Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire. Expert Review of Neurotherapeutics, 2013, 13, 1017-1029.	2.8	17
230	A patterned recombinant human IgM guides neurite outgrowth of CNS neurons. Scientific Reports, 2013, 3, 2267.	3.3	17
231	Vitamin D genes influence MS relapses in children. Multiple Sclerosis Journal, 2020, 26, 894-901.	3.0	17
232	Magnetic resonance imaging of immune cells in inflammation of central nervous system. Croatian Medical Journal, 2003, 44, 463-8.	0.7	17
233	Have we finally identified an autoimmune demyelinating disease?. Annals of Neurology, 2009, 66, 572-573.	5.3	16
234	Human-derived natural antibodies: biomarkers and potential therapeutics. Future Neurology, 2015, 10, 25-39.	0.5	16

#	Article	IF	Citations
235	Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases. JAMA Neurology, 2015, 72, 1346.	9.0	16
236	Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. , 2000, 47, 707.		16
237	Neurotrophin-4/5 promotes proliferation of oligodendrocyte-type-2 astrocytes (O-2A). Developmental Brain Research, 2000, 123, 87-90.	1.7	15
238	CD40L is Critical for Protection from Demyelinating Disease and Development of Spontaneous Remyelination in a Mouse Model of Multiple Sclerosis. Brain Pathology, 2000, 10, 1-15.	4.1	15
239	Transgenic Expression of the 3D Polymerase Inhibits Theiler's Virus Infection and Demyelination. Journal of Virology, 2009, 83, 12279-12289.	3.4	15
240	Polysialic acid as an antigen for monoclonal antibody <scp>HI</scp>gM12 to treat multiple sclerosis and other neurodegenerative disorders. Journal of Neurochemistry, 2015, 134, 865-878.	3.9	15
241	Induction of a gene expression program in dendritic cells with a cross-linking IgM antibody to the co-stimulatory molecule B7-DC. FASEB Journal, 2006, 20, 2408-2410.	0.5	15
242	Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression. Current Pharmaceutical Design, 2016, 22, 1049-1059.	1.9	15
243	Genetic Deletion of a Single Immunodominant T-cell Response Confers Susceptibility to Virus-induced Demyelination. Brain Pathology, 2007, 17, 184-196.	4.1	14
244	Heterogeneity of Pathogenesis in Multiple Sclerosis: Implications for Promotion of Remyelination. Journal of Infectious Diseases, 2002, 186, S248-S253.	4.0	13
245	STAT4â€•and STAT6â€signaling molecules in a murine model of multiple sclerosis. FASEB Journal, 2006, 20, 343-345.	0.5	13
246	TREM-2 Mediated Signaling Induces Antigen Uptake and Retention in Mature Myeloid Dendritic Cells. Journal of Immunology, 2008, 181, 7863-7872.	0.8	13
247	Deletion of Betaâ€2â€Microglobulin Ameliorates Spinal Cord Lesion Load and Promotes Recovery of Brainstem NAA Levels in a Murine Model of Multiple Sclerosis. Brain Pathology, 2012, 22, 698-708.	4.1	13
248	A comparison of human natural monoclonal antibodies and aptamer conjugates for promotion of CNS remyelination: where are we now and what comes next?. Expert Opinion on Biological Therapy, 2018, 18, 545-560.	3.1	13
249	Relapse recovery. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	13
250	Influence of Deletion of T Cell Receptor VÎ²Genes on the Theiler's Virus Model of Multiple Sclerosis. Autoimmunity, 1994, 19, 221-230.	2.6	12
251	Enhancement of central nervous system remyelination in immune and non-immune experimental models of demyelination. Multiple Sclerosis Journal, 1997, 3, 76-79.	3.0	12
252	Failure of treatment with Linomide or oral myelin tolerization to ameliorate demyelination in a viral model of multiple sclerosis. Journal of Neuroimmunology, 1998, 88, 111-119.	2.3	12

#	Article	IF	Citations
253	Pulsed Intravenous Methylprednisolone Therapy in Progressive Multiple Sclerosis: Need for a Controlled Trial. Archives of Neurology, 2004, 61, 1148-9.	4.5	12
254	Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. Neurology, 2022, 98, .	1.1	12
255	Human T-Cell Lymphotropic Virus Type I Sequences Detected by Nested Polymerase Chain Reactions Are Not Associated With Multiple Sclerosis. Mayo Clinic Proceedings, 1991, 66, 665-680.	3.0	11
256	Persistence of TheilerÊ¼s Virus Infection Following Promotion of Central Nervous System Remyelination. Journal of Neuropathology and Experimental Neurology, 1991, 50, 523-537.	1.7	11
257	The role of cellular immune response in Theiler's virus-induced central nervous system demyelination. Journal of Neuroimmunology, 2004, 147, 73-77.	2.3	11
258	Transgenic Expression of Viral Capsid Proteins Predisposes to Axonal Injury in aâ€ƒMurine Model of Multiple Sclerosis. Brain Pathology, 2011, 21, no-no.	4.1	11
259	Statin therapy and multiple sclerosis disability in a population-based cohort. Multiple Sclerosis Journal, 2012, 18, 358-363.	3.0	11
260	The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment. Expert Review of Clinical Immunology, 2013, 9, 535-549.	3.0	11
261	Pediatric Multiple Sclerosis Severity Score in a large US cohort. Neurology, 2020, 95, e1844-e1853.	1.1	11
262	The CD4-Mediated Immune Response Is Critical in Determining the Outcome of Infection Using Theiler's Viruses with VP1 Capsid Protein Point Mutations. Virology, 2000, 275, 9-19.	2.4	10
263	HLA-DQ Polymorphism Influences Progression of Demyelination and Neurologic Deficits in a Viral Model of Multiple Sclerosis. Molecular and Cellular Neurosciences, 2000, 15, 495-509.	2.2	10
264	A single dose of a neuron-binding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis. Journal of Neuroinflammation, 2015, 12, 83.	7.2	10
265	A monoclonal natural human IgM protects axons in the absence of remyelination. Journal of Neuroinflammation, 2016, 13, 94.	7.2	10
266	mi RNA contributions to pediatricâ€onset multiple sclerosis inferred from GWAS. Annals of Clinical and Translational Neurology, 2019, 6, 1053-1061.	3.7	10
267	Glial cells as therapeutic targets in progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 481-494.	2.8	10
268	Optimization of a 40-mer Antimyelin DNA Aptamer Identifies a 20-mer with Enhanced Properties for Potential Multiple Sclerosis Therapy. Nucleic Acid Therapeutics, 2019, 29, 126-135.	3.6	10
269	ICAM-1 is crucial for protection from TMEV-induced neuronal damage but not demyelination. Journal of NeuroVirology, 2002, 8, 452-458.	2.1	9
270	A New Humanized HLA Transgenic Mouse Model of Multiple Sclerosis Expressing Class II on Mouse CD4 T Cells. Annals of the New York Academy of Sciences, 2007, 1103, 112-117.	3.8	9

#	Article	IF	Citations
271	MRI findings in benign multiple sclerosis are variable. Journal of Neurology, 2007, 254, 539-541.	3.6	9
272	Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 857-876.	4.1	9
273	VÎ²8+ T cells protect from demyelinating disease in a viral model of multiple sclerosis. International Immunology, 2000, 12, 271-280.	4.0	8
274	Antigens to viral capsid and non-capsid proteins are present in brain tissues and antibodies in sera of Theiler's virus-infected mice. Journal of Virological Methods, 2001, 91, 11-19.	2.1	8
275	CD4+ T cells are important for clearance of DA strain of TMEV from the central nervous system of SJL/J mice. International Immunology, 2004, 16, 1237-1240.	4.0	8
276	Need for a paradigm shift in therapeutic approaches to CNS injury. Expert Review of Neurotherapeutics, 2012, 12, 409-420.	2.8	8
277	Therapeutics to Promote CNS Repair: A Natural Human Neuron-Binding IgM Regulates Membrane-Raft Dynamics and Improves Motility in a Mouse Model of Multiple Sclerosis. Journal of Clinical Immunology, 2013, 33, 50-56.	3.8	8
278	Several household chemical exposures are associated with pediatricâ€onset multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1513-1521.	3.7	8
279	Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis. Human Antibodies, 2017, 25, 121-129.	1.5	7
280	Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression. Current Pharmaceutical Design, 2016, 22, 1049-59.	1.9	7
281	Mechanisms of Virus-Induced Demyelination and Remyelination. Annals of the New York Academy of Sciences, 1988, 540, 240-251.	3.8	6
282	A 40â€cM Region on Chromosome 14 Plays a Critical Role in the Development of Virus Persistence, Demyelination, Brain Pathology and Neurologic Deficits in a Murine Viral Model of Multiple Sclerosis. Brain Pathology, 2003, 13, 519-533.	4.1	6
283	Lipid-specific IgMs induce antiviral responses in the CNS: implications for progressive multifocal leukoencephalopathy in multiple sclerosis. Acta Neuropathologica Communications, 2020, 8, 135.	5.2	6
284	Naturally Occurring Antibodies as Therapeutics for Neurologic Disease. Advances in Experimental Medicine and Biology, 2012, 750, 44-55.	1.6	6
285	Plasmonic nanohole arrays for label-free kinetic biosensing in a lipid membrane environment. , 2009, 2009, 1481-4.		5
286	Nonequivalence of Classical MHC Class I Loci in Ability to Direct Effective Antiviral Immunity. PLoS Pathogens, 2012, 8, e1002541.	4.7	5
287	Surface Plasmon Resonance Sensing on Naturally Derived Membranes: A Remyelination-Promoting Human Antibody Binds Myelin with Extraordinary Affinity. Analytical Chemistry, 2018, 90, 12567-12573.	6.5	5
288	Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. Journal of Child Neurology, 2019, 34, 148-152.	1.4	5

#	Article	IF	Citations
289	Deletion of Virus-specific T-cells Enhances Remyelination in a Model of Multiple Sclerosis. , 2014, 2, .		5
290	Dysglobulinemic neuropathy: Absence of immunoglobulin within myelin sheaths. Annals of Neurology, 1986, 19, 204-206.	5.3	4
291	Enumeration and Distribution of T-Cell Subsets, Macrophages, and IgG Positive Cells in the CNS of SJL/J Mice Infected with Theiler's Virus. Annals of the New York Academy of Sciences, 1988, 540, 657-660.	3.8	4
292	Delineation of the minimal encephalitogenic epitope of proteolipid protein peptide91â€“110 and critical residues required for induction of EAE in HLA-DR3 transgenic mice. Journal of Neuroimmunology, 2005, 161, 40-48.	2.3	4
293	Inability of bm14 Mice to Respond to Theilerâ€™s Murine Encephalomyelitis Virus Is Caused by Defective Antigen Presentation, Not Repertoire Selection. Journal of Immunology, 2005, 174, 2756-2762.	0.8	4
294	Human HLA-DR Transgenes Protect Mice from Fatal Virus-Induced Encephalomyelitis and Chronic Demyelination. Journal of Virology, 2008, 82, 3369-3380.	3.4	4
295	Novel Roles of the Picornaviral 3D Polymerase in Viral Pathogenesis. Advances in Virology, 2010, 2010, 1-9.	1.1	4
296	Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurology, 2013, 13, 173.	1.8	4
297	Demyelination with preferential MAG loss: A complex message from MS paraffin blocks. Journal of the Neurological Sciences, 2018, 385, 126-130.	0.6	4
298	Curvature Elasticityâ€Driven Leaflet Asymmetry and Interleaflet Raft Coupling in Supported Membranes. Advanced Materials Interfaces, 2018, 5, 1801290.	3.7	4
299	Antibody characterization using immunosignatures. PLoS ONE, 2020, 15, e0229080.	2.5	4
300	Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	4
301	Anti-Î¼ treatment suppresses immunoglobulin light-chain gene expression and Peyer's patch development. Molecular Immunology, 1989, 26, 351-358.	2.2	3
302	Remyelination as Neuroprotection. , 2005, , 389-419.		3
303	Human class I major histocompatibility complex alleles determine central nervous system injury versus repair. Journal of Neuroinflammation, 2016, 13, 293.	7.2	3
304	Remyelination-Promoting DNA Aptamer Conjugate Myaptavin-3064 Binds to Adult Oligodendrocytes In Vitro. Pharmaceuticals, 2020, 13, 403.	3.8	3
305	Nanogap dielectrophoresis combined with buffer exchange for detecting protein binding to trapped bioparticles. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2021, 611, 125829.	4.7	3
306	The Contribution of MHC Gene Products to Demyelination by Theilerâ€™s Virus. , 1987, , 747-756.		3

#	Article	IF	Citations
307	Differentiation-specific mRNA expression of a mouse bipotential glial cell line. Neuroscience Letters, 1998, 258, 21-24.	2.1	2
308	Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 22, 103-107.	2.0	2
309	An Assay that Predicts InÂVivo Efficacy for DNA Aptamers that Stimulate Remyelination in a Mouse Model of Multiple Sclerosis. Molecular Therapy - Methods and Clinical Development, 2018, 9, 270-277.	4.1	2
310	Acute vision loss in multiple sclerosis: Optic neuritis or central serous chorioretinopathy?. Multiple Sclerosis and Related Disorders, 2019, 27, 147-150.	2.0	2
311	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. , 1999, 46, 878.		2
312	Erichrome Stain for Myelin on Osmicated Tissue Embedded in Glycol Methacrylate Plastic. Journal of Histotechnology, 1989, 12, 35-36.	0.5	2
313	A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210914.	1.0	2
314	Dalfampridine for the treatment of ambulatory impairment in multiple sclerosis. Future Neurology, 2010, 5, 637-643.	0.5	1
315	Disease-modifying therapy and response to first-line treatment in pediatric multiple sclerosis. , 2011, , 96-100.		1
316	Formation of Biomembrane Microarrays with a Squeegee-based Assembly Method. Journal of Visualized Experiments, 2014, , .	0.3	1
317	Imaging of multiple sclerosis and related acquired demyelinating disorders in childhood. Journal of Pediatric Neuroradiology, 2015, 02, 057-072.	0.1	1
318	Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis. International Journal of Physical Medicine & Rehabilitation, 2016, 4, .	0.5	1
319	Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study. Journal of Visualized Experiments, 2016, , .	0.3	1
320	Timing of Future Remyelination Therapies and Their Potential to Stop Multiple Sclerosis Progression. Advances in Experimental Medicine and Biology, 2017, 958, 161-170.	1.6	1
321	A natural human monoclonal antibody protects from axonal injury in different CNS degenerative disease models. Future Neurology, 2018, 13, 23-29.	0.5	1
322	Quantitation of spinal cord demyelination, remyelination, atrophy, and axonal loss in a model of progressive neurologic injury. , 0, .		1
323	Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. , 2000, 47, 707.		1
324	The Repair of Central Nervous System Myelin. , 1997, , 253-264.		1

#	Article	IF	Citations
325	Biomarkers in radiologically isolated syndrome: The missing piece in the puzzle of treatment indication?. Journal of the Neurological Sciences, 2017, 375, 129.	0.6	1
326	A human anti-polysialic acid antibody as a potential treatment to improve function in multiple sclerosis patients. Journal of Nature and Science, 2015, 1, .	1.1	1
327	Polyclonal Ig: an immunopharmacon?. Trends in Immunology, 1994, 15, 341-342.	7.5	0
328	Multiple sclerosis: a unique immunopathological syndrome of the central nervous system. , 1996, , 89-105.		0
329	Chapter 13 Treatment of Catastrophic Multiple Sclerosis. Blue Books of Practical Neurology, 2003, 27, 207-216.	0.1	0
330	Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. Journal of Experimental Medicine, 2010, 207, 901-901.	8.5	0
331	Lipid Membranes: Curvature Elasticityâ€Driven Leaflet Asymmetry and Interleaflet Raft Coupling in Supported Membranes (Adv. Mater. Interfaces 23/2018). Advanced Materials Interfaces, 2018, 5, 1870117.	3.7	0
332	Strategies to Promote Central Nervous System Remyelination In Vivo. , 1997, , 297-311.		0
333	Magnetic resonance imaging, microscopy, and spectroscopy of the central nervous system in experimental animals. Neurotherapeutics, 2005, 2, 250-264.	4.4	0
334	Tryptophan Metabolites and Their Impact on Multiple Sclerosis Progression. Current Pharmaceutical Design, 2015, , .	1.9	0